



# Drug-induced neuro-respiratory alterations useful for physiotherapists

**Bruno Mégarbane, MD, PhD**

*Department of Medical and Toxicological Critical Care, Lariboisière Hospital,  
INSERM UMRS-1144, Paris-Cité University,  
Paris, France*

*[bruno.megarbane@lrb.aphp.fr](mailto:bruno.megarbane@lrb.aphp.fr)*

**No conflict of interest to declare**


# True or false?

- 1- There is an excellent parallelism between the coma Glasgow score and the gag reflex suppression in a patient with suspected drug-induced coma.
- 2- The right basal site of aspiration pneumonia is the most common regardless of the comatose patient's position.
- 3-  $\text{SpO}_2$  is a better surrogate marker of respiratory depression than  $\text{PaCO}_2$ .
- 4- Benzodiazepines are mainly responsible for a CNS respiratory depression.
- 5- Naloxone administration is at risk and systematically requires a medical prescription in a comatose patient with suspected opioid overdose.

# The three components of respiration


## a. Central Neural Control (Respiratory Drive)

controls inhalation and exhalation




## b. Sensory Input Systems

impact the rate and depth of respiration





## c. Respiratory Muscles and Lungs

carry out the mechanics of respiration





# Control of ventilation





# Physiological regulation of ventilation



# Mechanisms of drug-induced acute respiratory failure

## Type 1

Alteration of the  
ventilation/perfusion ratio

Hypoxemia + hypo/normocapnia  
 $\text{PaO}_2 < 8 \text{ kPa}$  /  $\text{PaCO}_2 < 6 \text{ kPa}$

Aspiration pneumonia +++

Atelectasia

Pneumonitis (ARDS)

Cardiogenic edema

Direct toxicity

MOF

## Type 2

Alveolar hypoventilation

Hypoxemia + hypercapnia  
 $\text{PaO}_2 < 8 \text{ kPa}$  /  $\text{PaCO}_2 > 6 \text{ kPa}$

Central apnea

Obstructive apnea

Bronchospasm

Neuromuscular blockage

# Drugs and pathophysiology of respiratory failure

Shunt effect

**Aspiration pneumonia**

**ARDS**

**Cardiogenic edema**

**All sedative drugs**

Stabilisants de membrane, paraquat

Cardiotropic drugs

Alveolar  
depression

**Central apnea**

**Obstructive apnea**

**Bronchospasm**

**Neuromuscular blockage**

**Opioids**, barbiturates, cyanide

**Benzodiazepines**, ethanol

Inhaled drugs/toxicants

Muscle-paralyzing agents,  
anticholinesterase agents



1

# Aspiration pneumonia



The non drug-specific mechanism of acute respiratory failure

# Pathogenesis and risk factors for aspiration

## Pathogenesis and risk factors for the development of pneumonia after macroaspiration

### Risk Factors

#### Impaired swallowing

Esophageal disease: dysphagia, cancer, stricture  
Chronic obstructive pulmonary disease  
Neurologic diseases: seizures, multiple sclerosis, parkinsonism, stroke, dementia  
Mechanical ventilation extubation

#### Impaired consciousness


Neurologic disease: stroke  
Cardiac arrest  
Medications  
General anesthesia  
Alcohol consumption

#### Increased chance of gastric contents reaching the lung

Reflux  
Tube feeding

#### Impaired cough reflex

Medications  
Alcohol  
Stroke  
Dementia  
Degenerative neurologic disease  
Impaired consciousness



Mandell LA. NEJM 2019

- Defense mechanisms to prevent aspiration include strong cough reflex, active mucociliary clearance mechanism, and effective immune system.
- Aspiration results from altered swallowing due to CNS dysfunction such as coma. Oropharyngeal or gastric contents can enter the lung. Impaired cough reflex increases the likelihood that aspirated material reach the lung

# Aspiration pneumonitis in an overdose population: frequency, predictors, and outcomes

Patients with aspiration pneumonitis: **1.6%** [1.2-2.0]

Higher ICU admission rate

Increased mortality: 8.5% vs. 0.4%; OR, **23** [9-60];  $p < .0001$ )

Prolonged ICU stay (**126 h** [62-210] vs. 14.7 h [7-23];  $p < .0001$ ).

Predictor	Odds Ratio	95% Confidence Interval
Age		
10-yr increase	1.18	1.01 – 1.38
Emesis		
No (reference)	—	—
Yes	2.41	1.34 – 4.34
Ingestion to hospital presentation time		
<4 hrs (reference)	—	—
4–24 hrs	2.89	1.41 – 5.96
>24 hrs	4.64	2.45 – 8.79

# Risk factors for prolonged ICU stay in self-poisoned patients

Selected parameters	Odds ratio	p Value
Demographics and history		
Age	1.02 (0.99; 1.04)	0.1
Psychiatric diseases	0.78 (0.38; 1.59)	0.5
Addiction	0.62 (0.31; 1.26)	0.2
Toxicants		
Psychotropic drugs	1.18 (0.53; 2.62)	0.7
Cardiotoxicants	0.68 (0.26; 1.73)	0.4
Ethanol	0.28 (0.11; 0.66)	0.005
Multidrug exposure	1.13 (0.52; 2.45)	0.8
Clinical parameters on admission		
SAPS II	1.01 (0.99; 1.03)	0.3
Glasgow coma score	0.98 (0.89; 1.06)	0.6
Complications		
Aspiration pneumonia	8.48 (4.28; 17.3)	<0.001
Cardiovascular failure <sup>a</sup>	1.55 (0.51; 5.43)	0.6
Cardiac contractility impairment <sup>b</sup>	0.64 (0.23; 1.76)	0.4
Cardiac arrest	0.15 (0.04; 0.52)	0.003
Seizures	2.49 (0.77; 8.73)	0.1
Acute kidney injury	3.15 (1.36; 7.39)	0.008
Acute liver failure	0.69 (0.25; 1.99)	0.5
Rhabdomyolysis	0.97 (0.44; 2.12)	0.9
Multiple organ failure	8.06 (3.43; 19.9)	<0.001
Outcome		
Delayed awakening <sup>c</sup>	8.64 (2.58; 40.7)	0.002
Management		
Veno-arterial ECMO	0.82 (0.23; 3.13)	

# Aspiration pneumonia in the poisoned patient: necessity of early airway management


Association between aspiration pneumonia onset and delayed intubation until arrival at the ED

N=72	Patients with Aspiration Pneumonia	Patients without Aspiration Pneumonia	p-Value
Women	12	27	-
Men	9	24	0.75
GCS of 8 or less	15	32	0.48
Emesis	8	7	0.046
Active charcoal	3	1	0.07
Delayed intubation to ED admission in unconscious patient	9	4	0.002

Montassier E. *J Emerg Med* 2012



# Glasgow coma score and risk for aspiration



# Relation of body position at the time of discovery with aspiration pneumonia in the poisoned comatose patients

Position	Aspiration pneumonia	GCS
Prone (n=20)	1 (5%)*	6 ± 3
Suppine (n=115)	48 (42%)	6 ± 3
Left Lateral (n=31)	8 (26%)	6 ± 3
Right lateral (n=21)	11 (52%)	6 ± 2
Semi-recumbant (n=20)	3 (15%)*	8 ± 2 <sup>\$</sup>

\* $p < 0.01$  vs other positions;  $^{\$}p < 0.05$  vs other positions

# Relationship between the position of the body position at the time of discovery and aspiration pneumonia on chest X-Ray


Position	Right Inf. Quadrant	Right Sup. Quadrant	Left Inf. Quadrant	Left Sup. Quadrant
Supine	69%	37%	20%	14%
Left lateral	57%	14%	29%	0%
Right lateral	80%	50%	30%	20%




# Tracheal intubation difficulty in the comatose poisoned patient

Difficult intubation is frequent in the pre-hospital setting (~11%). In poisonings, it averages 20%. Choosing the best sedative drugs for anesthesia induction is highly difficult

Adnet F. *Eur J Emerg Med* 1998




Patients  
"in between"



Adnet F. *Acad Emerg Med* 1998

# Intracuff pressures of endotracheal tubes in the management of airway emergencies: an observational study



- First measurement > 27 cmH<sub>2</sub>O in 79% patients (85/107)
- Mean value: 56 cm H<sub>2</sub>O in the extra-hospital patients and 69 cm H<sub>2</sub>O in the transferred patients
- A correction is required in 72% of the patients (77/107)





# Laryngeal injuries in relation to tracheal intubation

## Evaluation of post-extubation laryngeal injuries in 209 poisonings

	Epiglottitis	Ventricular bands	Vocal cord		Arytenoid		Subglottis	Number of patients (%)
			Right	Left	Right	Left		
Number of patients								
Normal	168	170	102	95	105	110	163	42 (20%)
With injury	41	39	107	114	104	99	46	167 (80%)
Number of separate scored lesions								
Mucosal edema	29	37	54	57	86	84	32	135 (65%)
Ulceration	11	2	38	38	14	13	10	65 (31%)
Reduced mobility	—	—	14	11	—	—	—	25 (12%)
Immobility	—	—	1	5	—	—	—	6 (3%)
Granuloma	1	—	12	10	2	—	4	14 (7%)
Subluxation	—	—	—	—	2	2	—	4 (2%)
Total <sup>a</sup>	41	39	119	121	104	99	46	167 (80%)

- Median duration of intubation: 24 h (13-52)
- Non-planned self-extubation : 27%

# The main intubation-related laryngeal injuries



Mucosal injuries



Diffused inflammation



Cartilage subluxation



Ulcer




Vestibular fold granuloma












Tracheomalacia

# Respiratory system toxicity secondary to organophosphorus poisoning






## Effects of hematogenous (indirect) vs aspirated (direct) organophosphorus on minipig lung



# Imaging to diagnose aspiration pneumonia



Cavitary infiltrate in the right lower lobe

Mandell LA. *NEJM* 2019



# Cocaine-induced cardiogenic pulmonary edema

36-yr-old cocaine abuser woman who presented with shortness of breath and chest pain after smoking crack

Cardiac toxicity



Extensive bilateral heterogeneous central and parahilar opacities



Bilateral heterogeneous opacities

Restrepo CS. Radiographics 2007

# Crack lung

Acute syndrome after the inhalation of (free base) cocaine  
Presentation: Fever, hypoxemia, hemoptysis, respiratory failure



Opacities with peripheral distribution




Extensive bilateral ground-glass opacities and airspace consolidation.


**Suggested mechanisms:** high temperature of volatilized drug, impurities, local vasoconstriction, macrophage activation

*Restrepo CS. Radiographics 2007*

# Suspicion of aspiration pneumonia in the comatose poisoned patient



# Value of CRP in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia



CRP >75 mg/L is associated with aerobic bacterial content of aspiration pneumonia



(Se=87%, Spe=76%, PPV=78%, NPV=87%).

By contrast to temperature and WBC, early CRP measurement is useful for diagnosis and perhaps in determining the need for invasive sampling.

Adnet F. *Chest* 1997

# Impact on antimicrobial consumption of PCT-guided antibiotics for aspiration pneumonia in comatose ventilated patients: a randomized controlled study

RCT



PCT to guide therapy vs. clinical, biological and radiological criteria, does not modify exposure to antibiotics in comatose intubated patients



# Antibiotic therapy in ventilated comatose patients following aspiration: differentiating pneumonia from pneumonitis

Prospective cohort study


- Among ventilated comatose patients, those without clinical, laboratory, or radiologic evidence of bacterial aspiration pneumonia did not require antibiotics.
- In those with suspected bacterial aspiration pneumonia, stopping empirical antibiotic therapy when routine telescopic plugged catheter sampling recovered no microorganisms was nearly always effective.
- This strategy may be a valid alternative to routine full-course antibiotic therapy. Only half the patients with suspected bacterial aspiration pneumonia had confirmed diagnosis.

2

## Central respiratory depression




# Effect of CNS depressant exposure on the $\text{CO}_2$ response curve



Pharmaceuticals and recreational depressant drugs can suppress one or more steps in respiration and patency.

Common depressors are opioids and barbiturates, >> benzodiazepines, Z drugs, and ethanol.


# Opioids : the first cause of toxic death



Jones CM. JAMA 2013

# The US Opioid-Overdose Epidemic

## Opioid sales, admissions for opioid-abuse treatment and deaths due to opioid overdose, 1999-2010




Volkow ND. *NEJM* 2014






# Opioid-prescribing patterns of emergency physicians and risk of long-term use



- Rates of opioid prescribing varies widely between low-intensity and high-intensity prescribers (7.3% vs. 24.1%).
- Long-term opioid use is higher among patients treated by high-intensity prescribers than among patients treated by low-intensity prescribers (adjusted OR, 1.30 [1.23 to 1.37];  $P < 0.001$ )

# A 1980 NEJM letter on the risk of opioid addiction when prescribed for chronic pain

A 5-sentence letter published in the NEJM in 1980 was uncritically cited as evidence that addiction was rare with long-term opioid therapy [439/608 (72%)]



Leung PTM. NEJM 2017


Porter J, Jick H. Addiction rare in patients treated with narcotics. NEJM 1980;302:123

# The role of Big Pharma: Accused of causing $\frac{1}{2}$ million deaths

## Sackler Family





The 19<sup>th</sup> wealthiest family in the US  
with a fortune of \$13 billion in 2016



# Opioid-related deaths in the US (2000-2022)

~ 64,000 deaths / year




New York Times 2017






# Chemistry of fentanyl derivatives





# Presentation of illicitly produced designer fentanyls

25 mg butyrfentanyl labeled bottles, each spray yields 0.25 mg and the content is sufficient for 95-105 puffs.



# The usual presentation of opioid overdose

1. Respiratory depression
2. Miosis
3. Stupor
4. Hepatic injury from acetaminophen or hypoxemia
5. Myoglobinuric renal failure
6. Rhabdomyolysis
7. Absent or hypoactive bowel sounds
8. Compartment syndrome
9. Hypothermia
10. Possible presence of one or more fentanyl patches




All opioids produce a similar toxidrome in excessive dosing.

SpO<sub>2</sub> and RR are surrogate indicators of ventilatory drive but provide limited information on drug-related effects on ventilatory control


PaCO<sub>2</sub> and V<sub>M</sub> are direct measures of ventilation but difficult to assess continuously

Boyer EW. NEJM 2012

Identification by  
analytical  
techniques  
combining liquid  
chromatography  
+ mass  
spectrometry  
(LC-HRMS,  
LC-MS/MS,  
LC-HRMS/MS)




## Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long-term opioid therapy



Rose AR. *J Clin Sleep Med* 2014

## Risk of death from opioid overdose in relation to the treatment duration




AGO graph from Massachusetts Department of Public Health data

# Risk factors for severe respiratory depression from prescription opioid overdose

<i>Prescription opioid</i>	<i>SRD rate (%)</i>	<i>RR (descending)</i>	<i>95% CI</i>
Tapentadol	2/2 (100)	27.0	3.9–185
Fentanyl	5/6 (83.3)	22.5	3.2–159
Oxymorphone	2/3 (66.7)	18.0	2.2–144
Methadone	59/116 (50.9)	13.7	2.0–95
Hydromorphone	4/9 (44.4)	12.0	1.5–94
Morphine	5/12 (41.7)	11.3	1.5–86
Oxycodone	40/124 (32.3)	8.7	1.3–60
Hydrocodone	9/31 (29.0)	7.8	1.0–58
Buprenorphine	2/7 (28.6)	7.7	0.8–73
Tramadol	3/12 (25.0)	6.8	0.8–58
Codeine	1/27 (3.7)	1.0 (ref)	–




# Opioid-attributed death: role of the dose?



Methadone-related deaths

Häkkinen M. *Forensic Sci Int* 2012



Buprenorphine-related deaths

Häkkinen M. *Eur J Clin Pharmacol* 2011

# Could chest wall rigidity be a factor in the rapid death from illicit fentanyl abuse?

(N= 48)

Acute chest wall rigidity is a well-recognized complication

1- Deaths occurred with fentanyl in the therapeutic range (1-2 ng/ml) in apparent non-naïve opiate abusers




questioning the onset of dose-dependent respiratory arrest as mechanism of death

2- Lack of measurable norfentanyl in half of the cases despite high fentanyl  
- No correlation between elevated fentanyl and rises in norfentanyl



suggesting a very rapid death, consistent with acute chest rigidity

# Drug-drug interactions





Abundance of hypnotics and drugs of abuse in blood (black) and proximal hair segments (white) in 99 methadone-related fatalities.

Based on segmental hair analysis, continuous exposure of methadone suggested that reduced tolerance of methadone is not a critical factor among methadone-related fatalities.

In contrast, a high abundance of co-ingested CNS depressants suggested that adverse effects from drug-drug interactions are more important risk factors for fatal outcome

Nielsen MK. *Forensic Sci Int* 2015


# Vulnerability related to gene polymorphism: Near-fatal tramadol cardiotoxicity in a *CYP2D6* ultrarapid metabolizer



- Ultrarapid metabolizer phenotype suggested by tramadol/M1 metabolic ratio
- Heterozygous for duplicated wt allele predictive of *CYP2D6* ultrarapid metabolizer phenotype
- + Ketoconazole at inhibitory concentration of *CYP3A/CYPB6* (200 ng/ml)

# The role of tolerance and abstinence

## Tolerance theory



Tolerance



Dose increase



Death

White JM. *Addiction* 1999

## Abstinence theory



Abstinence



Tolerance decrease



Re-consumption




Death

Druid H. *Forensic Sci Int* 2007



# Naloxone: pharmacology properties

- Pure opioid antagonist at mu (high affinity), kappa, and delta receptors
- No agonist properties
- High first-pass metabolism (poor oral bioavailability)
- Short-plasma half-life 50 min
- Duration of action: 1-4 h
- Administered IV, IM, SC, IN



Widely used to reverse opioid toxicity

Dose-dependent reversal of opioid agonist effects

High dose may precipitate acute opioid withdrawal syndrome

# Comparison of heroin, methadone and BUP overdoses

	Heroin (N = 26)	Buprenorphine (N = 39)	Methadone (N = 19)	p
Suicide	12%	18%	58%	0.0007
Co-ingestions	73%	95%	89%	0.04
Glasgow Coma Score	5 [3 - 9]	7 [4 - 10]	4 [3 - 10]	0.1
Respiratory rate	10 [6 - 13]	12 [8 - 15]	10 [6 - 13]	0.4
SpO <sub>2</sub> (%)	82 [64 - 95]	94 [87 - 98]	91 [82 - 97]	0.05
pH	7.29 [7.17-7.34]	7.35 [7.24-7.38]	7.33 [7.23-7.42]	0.07
PaCO <sub>2</sub> (mmHg)	51 [45 - 55]	50 [45 - 66]	50 [36 - 57]	0.7
Mechanical ventilation	46%	41%	47%	0.6
Response to naloxone	81%	0%	71%	<0.0001
Response to flumazenil	0%	87%	60%	0.02



# Preventing opioid overdose deaths With take-home naloxone



- Death from opioid overdose occurs frequently at home, 1-3 h after exposure and often in the presence of bystanders (80%)
- BCLS by bystanders are generally not sufficient



Number of  
programs of  
naloxone  
distribution

Number of  
naloxone vials  
distributed over  
one year

Number of  
program  
participants

Number of reported  
opioid overdose  
reversals

136

140 053

152 283

26 463


3

## Peripheral respiratory depression




# Mechanisms of respiratory insufficiency in coma involving benzodiazepines

Obstructive apnea



Non-intubated patient before flumazenil





Gueye P. J Toxicol Clin Toxicol 2002

Increase in the resistive load and respiratory work






# Obstructive mechanism of respiratory insufficiency in benzodiazepine-induced coma

Tracheal intubation



Flumazenil injection



## Hypothesis: PD interaction with addition of different physiological effects

Mégarbane B. *Forensic Int Sci* 2011

Benzodiazepines :

- Alteration of Upper Airways Dilators ( $GABA_A$ )  
→ hypopnea, obstructive apnea
- Diaphragmatic dysfunction



Increase of the workload of breathing

Opioids

- Decrease of the ventilatory response to
  - Inspiratory load
  - Hypoxia
  - Hypercapnia




Depression of the ventilation centres




The combination  
of effects  
may result in  
respiratory  
depression and  
death

# Should we use flumazenil in presumed toxic coma? (1)

## Patient's awakening



## CGS improvement




# Should we use flumazenil in presumed toxic coma? (2)

Major ADR

Anxiety

Vomiting

Minor ADR





# Flumazenil does not increase the global costs of patient management in the ICU

Factor	Flumazenil	Placebo	p Value
Number	19	22	
Emergency room	244 ± 106	276 ± 111	NS
Nursing	140 ± 59	151 ± 51	NS
ER physician fee	93 ± 29	98 ± 33	NS
Drug	101 ± 57	5 ± 2	<.001
Inpatient	402 ± 1920	1258 ± 1100	NS
Medical consult	148 ± 77	109 ± 27	NS
ICU consult	400 ± 71	276 ± 63	NS
ICU	327 ± 2410	1245 ± 490	<sup>b</sup>
Total cost	1524 ± 2520	1432 ± 1420	NS

<sup>a</sup>Canadian dollar = 0.73 United States dollar; <sup>b</sup>sample size inadequate to compare costs.



Barnett R. *Crit Care Med* 1999



# Guidelines for routine flumazenil use

- 0.1 to 0.3 mg IV bolus
- Titration to avoid withdrawal syndrome
- More elevated dosage regimen if multi-drug poisoning: up to 2 mg bolus
- Efficient in poisonings with assimilated molecules (zopiclone and zolpidem)
- Caution if tricyclic antidepressants or carbamazepine co-ingestion
- Add bolus or continuous infusion (0.3-0.5 mg/h) to maintain consciousness
- Significant improvement in respiratory conditions to avoid tracheal intubation
  
- Debated utilization in ethanol poisoning or liver encephalopathy
- Efficient and safe utilization in elderly, children, babies, pregnant women

Weinbroum AA. *Drug Safety* 1997

## Flumazenil in children:

- 10-20  $\mu\text{g/kg}$  IV bolus
- Experience (N=83; 2 years [3 months,12 yrs]): excellent tolerance, no convulsion

Kreshak AA. *Pediatr Emerg Care* 2012

**Administer  
flumazenil**

**Do not administer  
flumazenil**

**Clinical findings**

↘ tonus  
↘ reflexes  
Plantar R: flexor  
ECG: normal

Agitation  
↗ tonus  
↗ reflexes  
Plantar R: extension  
Membrane stabilizing

BZD-related coma :  
No ↗ tonus,  
No abnormal plantar R  
No Babinski

**Life-threatening condition**

Absent  
(HR, BP: N)

SBP <80mmHg  
RR >30/min  
Cyanosis

A non-complicated  
BZD poisoning does  
not result in life-  
threatening conditions

**Non specific complications**

Absent

Hypothermia <34°C  
Aspiration PN, hypoxemia

Complications may  
require specific  
treatment

**Seizure risk**

Absent

Past history of seizure  
Convulsive toxicants  
(antidepressants)

The most frequent  
mixed intoxication :  
antidepressant

4

## The GHB threat





# Recreational GHB/GBL use and overwhelming issue of drug-facilitated sexual assaults

- GHB: colorless and odorless slightly salty/bitter liquid
- GBL: colorless oily water-soluble liquid
- **Dosage:** 2-5 g /dose with 1-3h interdosages, difficult calibration



## Préoccupante mode du GBL, une drogue proche du GHB, dans les clubs parisiens

Par AFP — 17 avril 2018 à 13:56

## Un jeune homme meurt d'une overdose de GBL

Un drame qui met en lumière le grand retour, dans le milieu de la nuit, de ce produit particulièrement dangereux. Enquête.



# Toxicity attributed to GHB

- Dose- and concentration-effect relationships

Dose (mg/Kg)	Symptoms
10	Amnesia, myorelaxation, hypotonic, dizziness, myoclonus
20 - 30	Euphoria followed by sleepiness
30 - 50	Sedation, nausea/vomiting
50 - 100	Non-reactive coma (G-hole), respiratory depression, seizures, bradycardia, hypotension, nystagmus, myosis/mydriasis


- Tight therapeutic index
- Inter-individual variability
- Tolerance development if repeated use
- Aspiration,  $\downarrow$ K<sup>+</sup>,  $\uparrow$  WBC,  $\uparrow$ CK, AVB
- Withdrawal: 1-6h, peak 24h, duration 14d





# Pharmacodynamics

GBL: No biological activity




Endogenous GHB (blood < 5 µg/mL and urine < 10 µg/mL)


# GHB/GBL metabolism



GABA aminotransferase




succinic semialdehyde dehydrogenase




→ Krebs Cycle  
↑  
CO<sub>2</sub>

GHB dehydrogenase


succinic semialdehyde reductase



peripheral  
lactonase




alcohol  
dehydrogenase



Activity half-life: 1-3 h  
Consciousness impairment <3h  
Detection: 8h (plasma) et 12h (urine)





## Mixed GHB/GBL poisonings



Miro O. *Tox Lett* 2017

# Rapidity of awakening in GHB poisoning

**21 participants to 6 rave parties admitted with  $GCS \leq 8$**

15/21: positive GHB screening

Plasma [GHB] : 212  $\mu\text{g/ml}$  (112 - 430)

14/15: multi-drug ingestions


$GCS \leq 8$  during 90 min (30 - 105)

$GCS$  change from  $\leq 8$  to  $\geq 12$ : 30 min (10 - !)

**Patient subgroup with  $GCS = 3$ :**

Remained at  $GCS$  3 during 60 min (30 - 110)

$GCS$  change from 3 to 15 in 30 min (20 - 60)



**No patient was further intubated**

# Take home messages

- **Aspiration pneumonia** is common in the comatose patient. Risk factors include **impairment of swallowing & alteration in consciousness**. Aspiration pneumonia is associated with **severity**, prolonged ICU stay, and **increased mortality**.
- **Drug-induced respiratory depression** is frequent. CNS depression attributed to **opioid and GHB** represents a growing concern. **Diagnosis** at the bedside is based on respiratory rate, SpO<sub>2</sub> and blood gas. Management is supportive.
- In patients with GCS <8, **tracheal intubation** should not be systematic. Decision should take into account the drug properties and its PK as well as the level of encephalopathy and respiratory/circulatory findings.
- **Antidotes** (naloxone and flumazenil, according to the toxidrom) can avoid intubation in selected patients. Their use is safe if respecting contra-indications.
- Adjunctive role of the **physiotherapist** to prevent and treat complications resulting from drug-related neuro-respiratory effects